MedCity News August 12, 2024
FDA approval of Ascendis Pharma’s Yorvipath is just in time for patients with hypoparathyroidism as Takeda Pharmaceutical will soon stop making the only drug therapy for the rare disorder. But competition could come from others, including an AstraZeneca peptide in late-stage development.
Patients with hypoparathyroidism have been clamoring for an alternative to a Takeda Pharmaceutical therapy set to cease production by the end of the year, leaving them with no drug treatments. FDA approval of an Ascendis Pharma drug finally gives them another one, albeit much later than expected.
Ascendis Pharma announced Monday that the FDA approved its hypoparathyroidism therapy, a peptide drug intended to bring deficient levels of thyroid hormone to within the normal range in adults. The regulatory...
Today's Sponsors
Today's Sponsor